Evidence map›Paper›PMID 24328127›Full record

ArticleBiochemistry2014

Assembly of an activated rhodopsin-transducin complex in nanoscale lipid bilayers.

Aaron M D'Antona, Guifu Xie, Stephen G Sligar, Daniel D Oprian

Abstract read
In one paragraph

Article in Biochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Selection of an ASIC1a-blocking combinatorial antibody that protects cells from ischemic death.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  2. Article
  3. Article
  4. Conformational equilibria of light-activated rhodopsin in nanodiscs.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Aaron M D'AntonaDepartment of Biochemistry and Volen Center for Complex Systems, Brandeis University , Waltham, Massachusetts 02454, United States.
Guifu Xie
Stephen G Sligar
Daniel D Oprian
Brandeis University · USUniversity of Illinois Urbana-Champaign · US

Funding

STRUCTURE/FUNCTION STUDIES OF RHODOPSINR01EY007965 · NEI · BRANDEIS UNIVERSITY · PI OPRIAN, DANIEL D · 1989 to 2017
$6.2M
METALLOENZYME MECHANISMSR01GM033775 · NIGMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI SLIGAR, STEPHEN G. · 1985 to 2014
$5.2M
Structural and Biochemical Studies of the Metarhodopsin II-Transducin ComplexF32EY018542 · NEI · BRANDEIS UNIVERSITY · PI D'ANTONA, AARON M · 2008 to 2008
$47k
NEI NIH HHS EY007965NEI NIH HHS EY18542NEI NIH HHS F32 EY018542NEI NIH HHS R01 EY007965NIGMS NIH HHS GM075365NIGMS NIH HHS GM33775NIGMS NIH HHS R01 GM033775
6 · The paper itself

Abstract

The formation and characterization of an activated complex of the visual pigment rhodopsin and its downstream signaling partner transducin have been the subject of intense focus by several research groups. While the subunit composition of the activated complex is still the subject of some controversy, our laboratory [Xie, G., D'Antona, A. M., Edwards, P. C., Fransen, M., Standfuss, J., Schertler, G. F. X., and Oprian, D. D. (2011) Biochemistry 50, 10399-10407] and that of Ernst et al. [Ernst, O. P., Gramse, V., Kolbe, M., Hofmann, K. P., and Heck, M. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 10859-10864] find that the two proteins are present in a 1/1 molar ratio. Unfortunately, these data could not distinguish a ratio of 1/1 from ratios of 2/2, 3/3, etc. For this reason, we reinvestigated the issue of stoichiometry of the activated complex, exploiting the ability of Nanodisc lipid bilayers to isolate single molecules of rhodopsin. We show here that the purified complex in Nanodiscs contains an activated rhodopsin with a covalently bound all-trans-retinal chromophore, that transducin has an empty nucleotide-binding pocket, that the isolated complex is active and dissociates upon addition of guanine nucleotide, and that the stoichiometry corresponds to exactly one molecule of rhodopsin and one molecule of transducin.

Indexed as

Guanine NucleotidesLipid BilayersNanostructuresRhodopsinTransducinGuanine NucleotidesLipid BilayersRhodopsinTransducin

Identifiers

PMID24328127
PMCPMC3939051
OpenAlexW2093929298

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.